Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| APPLIED GENETIC TECHNOLOGIES CORPAGTC · Entity 121949 | Chief Medical Officer | July 17, 2017 | July 18, 2017 |
| OCULAR THERAPEUTIX, INCOCUL · Entity 273 | President, Ophthalmology & CMO | February 03, 2022 | February 07, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
APPLIED GENETIC TECHNOLOGIES CORP
Report date July 17, 2017 · Filed July 18, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.90 · Expires 2027-07-17 | Direct | 25,000 |
Reported balance
After 2017-07-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-07-17 · Grant · Acquired 25,000 · Balance 25,000 F1: The option becomes exercisable in equal monthly installments over four years from the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The option becomes exercisable in equal monthly installments over four years from the date of grant.
OCULAR THERAPEUTIX, INC
Report date February 03, 2022 · Filed February 07, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 313,335 |
Reported balance
After 2022-02-03 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-02-03 · Grant · Acquired 63,333 · Balance 313,335 F1: On February 3, 2022, the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan of Ocular Therapeutix, Inc. (the "Company"). Each RSU represents a right to receive one share of the Company's common stock. Subject to the reporting person's continued service to the Company, the RSUs will vest over three years, with 1/3 of the shares underlying the RSUs vesting on the one-year anniversary of the date of grant and an additional 1/3 of the shares underlying the RSUs vesting at the end of each successive one-year period thereafter. F2: Includes (i) 63,333 shares of common stock of the Company underlying unvested RSUs and (ii) 2 shares of the Company's common stock acquired under the 2014 Ocular Therapuetix, Inc. Employee Stock Purchase Plan on December 31, 2021. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.27 · Expires 2032-02-02 | Direct | 190,000 |
Reported balance
After 2022-02-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-02-03 · Grant · Acquired 190,000 · Balance 190,000 F3: Vests over four years, vesting 1/48 monthly beginning on the one-month anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: On February 3, 2022, the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan of Ocular Therapeutix, Inc. (the "Company"). Each RSU represents a right to receive one share of the Company's common stock. Subject to the reporting person's continued service to the Company, the RSUs will vest over three years, with 1/3 of the shares underlying the RSUs vesting on the one-year anniversary of the date of grant and an additional 1/3 of the shares underlying the RSUs vesting at the end of each successive one-year period thereafter.
F2: Includes (i) 63,333 shares of common stock of the Company underlying unvested RSUs and (ii) 2 shares of the Company's common stock acquired under the 2014 Ocular Therapuetix, Inc. Employee Stock Purchase Plan on December 31, 2021.
F3: Vests over four years, vesting 1/48 monthly beginning on the one-month anniversary of the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 03, 2022 Filed Feb 7, 2022 19:29 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | GrantStock Option (Right to Buy) · Derivative | 190,000 | $0.00 Strike: $5.27 | $0.00 |
DisclosureSEC source: 0001104659-22-012919 · tm225652-2_4seq1.xml · derivative · entry 2 Goldstein Michael H. · CIK 0001691259 · President, Ophthalmology & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,000 Underlying: Common Stock · 190,000 shares Expires 2032-02-02 F3 · derivative.exercise_date: Vests over four years, vesting 1/48 monthly beginning on the one-month anniversary of the date of grant. Read SEC document |
| February 03, 2022 Filed Feb 7, 2022 19:29 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | GrantCommon Stock | 63,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-012919 · tm225652-2_4seq1.xml · nonDerivative · entry 1 Goldstein Michael H. · CIK 0001691259 · President, Ophthalmology & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 313,335 F1 · shares: On February 3, 2022, the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan of Ocular Therapeutix, Inc. (the "Company"). Each RSU represents a right to receive one share of the Company's common stock. Subject to the reporting person's continued service to the Company, the RSUs will vest over three years, with 1/3 of the shares underlying the RSUs vesting on the one-year anniversary of the date of grant and an additional 1/3 of the shares underlying the RSUs vesting at the end of each successive one-year period thereafter. F2 · balance_after: Includes (i) 63,333 shares of common stock of the Company underlying unvested RSUs and (ii) 2 shares of the Company's common stock acquired under the 2014 Ocular Therapuetix, Inc. Employee Stock Purchase Plan on December 31, 2021. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 16:31 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | GrantStock Option (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $18.31 | $0.00 |
DisclosureSEC source: 0001104659-21-025787 · tm217246d5_4seq1.xml · derivative · entry 1 Goldstein Michael H. · CIK 0001691259 · President, Ophthalmology & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2031-02-16 F1 · derivative.exercise_date: Vests over four years, vesting 1/48 monthly beginning on the one-month anniversary of the date of grant. Read SEC document |
| January 30, 2020 Filed Feb 3, 2020 18:27 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | GrantStock Option (Right to Buy) · Derivative | 215,000 | $0.00 Strike: $4.39 | $0.00 |
DisclosureSEC source: 0001104659-20-009939 · a4.xml · derivative · entry 1 Goldstein Michael H. · CIK 0001691259 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,000 Underlying: Common Stock · 215,000 shares Expires 2020-01-29 F1 · derivative.exercise_date: Vests over four years, vesting 1/48 monthly beginning on the one-month anniversary of the date of grant. Read SEC document |
| May 28, 2019 Filed May 30, 2019 16:10 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | PurchaseCommon Stock | 12,000 | $2.51 | $30,120.00 |
DisclosureSEC source: 0001104659-19-032741 · a4.xml · nonDerivative · entry 1 Goldstein Michael H. · CIK 0001691259 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,686 Read SEC document |
| March 15, 2019 Filed Mar 18, 2019 18:20 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | PurchaseCommon Stock | 10,000 | $4.15 | $41,500.00 |
DisclosureSEC source: 0001104659-19-015691 · a4.xml · nonDerivative · entry 1 Goldstein Michael H. · CIK 0001691259 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,686 F1 · balance_after: Includes 2,986 shares acquired under the 2014 Ocular Therapeutix, Inc. Employee Stock Purchase Plan on December 31, 2018. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 18:26 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $4.10 | $0.00 |
DisclosureSEC source: 0001104659-19-000887 · a4.xml · derivative · entry 1 Goldstein Michael H. · CIK 0001691259 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2029-01-01 F1 · derivative.exercise_date: Vests over four years, vesting 1/48 monthly beginning on the one-month anniversary of the date of grant. Read SEC document |
| January 31, 2018 Filed Feb 2, 2018 16:36 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | GrantStock Option (Right to Buy) · Derivative | 83,500 | $0.00 Strike: $5.47 | $0.00 |
DisclosureSEC source: 0001104659-18-006263 · a4.xml · derivative · entry 1 Goldstein Michael H. · CIK 0001691259 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,500 Underlying: Common Stock · 83,500 shares Expires 2028-01-30 F1 · derivative.exercise_date: Vests over four years, vesting 1/48 monthly beginning on the one-month anniversary of the date of grant. Read SEC document |
| October 02, 2017 Filed Oct 3, 2017 17:24 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | GrantStock Option (Right to Buy) · Derivative | 135,000 | $0.00 Strike: $6.30 | $0.00 |
DisclosureSEC source: 0001104659-17-060662 · a4.xml · derivative · entry 1 Goldstein Michael H. · CIK 0001691259 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,000 Underlying: Common Stock · 135,000 shares Expires 2027-10-01 F1 · derivative.exercise_date: Vests over four years, with 25% of the shares underlying the option vesting on the one-year anniversary of Goldstein's first date of employment and 2.0833% of the shares vesting monthly thereafter. Read SEC document |
| July 17, 2017 Filed Jul 18, 2017 20:39 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $4.90 | $0.00 |
DisclosureSEC source: 0000899243-17-018471 · doc4.xml · derivative · entry 1 Goldstein Michael H. · CIK 0001691259 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2027-07-17 F1 · derivative.exercise_date: The option becomes exercisable in equal monthly installments over four years from the date of grant. Read SEC document |
| December 01, 2016 Filed Dec 2, 2016 18:38 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | GrantStock Option (right to buy) · Derivative | 180,000 | $0.00 Strike: $8.70 | $0.00 |
DisclosureSEC source: 0000899243-16-034871 · doc4.xml · derivative · entry 1 Goldstein Michael H. · CIK 0001691259 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,000 Underlying: Common Stock · 180,000 shares Expires 2026-12-01 F1 · derivative.exercise_date: Option becomes exercisable for 25% of the underlying shares on the first anniversary of the grant date, and thereafter becomes exercisable for the remaining underlying shares in equal monthly installments over three years, resulting in the option being exercisable for 100% of the underlying shares on the fourth anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.